The analysis indicated that with significant heterogeneity, the increase of gal-3 level was potentially relevant to a greater risk of MACEs in patients with DCM (HR =1.10, 95% CI [1.00–1.21], I2 = 65.7%, p = 0.008). This evidence concerns the gene LGALS3 and familial dilated cardiomyopathy.